Literature DB >> 16502598

Alkaline encrusted pyelitis.

S Van Hooland1, A K Vandooren, E Lerut, R Oyen, B Maes.   

Abstract

Alkaline encrusted pyelitis is an infectious disease characterised by encrustations in the wall of the upper urinary tract, surrounded by severe inflammation. Destruction of native kidneys and kidney grafts may occur, resulting in end stage renal failure. Corynebacterium group D2, an urea splitting microorganism, is nearly exclusively associated with this disease. The most important predisposing factors are previous urological procedures and an immunosuppressed state. In a suggestive clinical context, diagnosis should be made with unenhanced computed tomography findings and bacteriologic isolation of the responsible microorganism. The treatment is threefold: appropriate antibiotic therapy, by preference with glycopeptides, acidification of urine and chemolysis, and if needed, surgical removal of encrustations. We report the case of a patient who was diagnosed with this rare condition and could escape maintenance dialysis after correct diagnosis was made and conservative treatment was started using antibiotics and combined oral and local acidification.

Entities:  

Mesh:

Year:  2005        PMID: 16502598     DOI: 10.1179/acb.2005.055

Source DB:  PubMed          Journal:  Acta Clin Belg        ISSN: 1784-3286            Impact factor:   1.264


  3 in total

Review 1.  Nephrolithiasis by Corynebacterium urealyticum infection: literature review and case report.

Authors:  Laura Cappuccino; Paolo Bottino; Adele Torricella; Roberto Pontremoli
Journal:  J Nephrol       Date:  2014-02-22       Impact factor: 3.902

2.  Arcanobacterium pyogenes and encrusted pyelitis.

Authors:  Albert Semaan; Georges Abi Tayeh; Josselin Abi Chebel; Rabih Hallit; Matta Matta; Pascal Hajj
Journal:  Future Sci OA       Date:  2019-12-09

Review 3.  Encrusted Uropathy: A Comprehensive Overview-To the Bottom of the Crust.

Authors:  Els Van de Perre; Gina Reichman; Deborah De Geyter; Caroline Geers; Karl M Wissing; Emmanuel Letavernier
Journal:  Front Med (Lausanne)       Date:  2021-01-21
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.